International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer

The T-REX study aims to clarify the actual status of metastatic lymph node (LN) distribution in colon cancer and provide reliable evidence regarding the optimal length of bowel resection and the extent of central lymph node dissection in colon cancer surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colon Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Erlangen, Erlangen, Bavaria, Germany

About this study

In colon canser, the incidence of metastasis in the pericolic lymph nodes (LNs) located along the bowel and marginal artery is high. The optimal extent of bowel resection is closely associated with how we define 'regional' pericolic LNs, which should be resected because of the risk of metastasis. However, there are no standardised criteria for 'regional' LNs in the pericolic area.

To establish a consensus for the extent of bowel resection and appropriate central LN dissection, international prospective stdies focusing on the distribution of metastatic LNs along the bowel and the primary feeding artery are conducted.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologically proven colon adenocarcinoma
Pathological stage Ⅰ, Ⅱ or Ⅲ
Potentially curative surgery
Informed consent for observational data collection

Exclusion criteria

Tis (mucosal cancer)
Multiple colon cancers
All patients with preoperative adjuvant therapy

Treatment and study plan

Primary outcomes

Distribution of metastatic LNs

Time frame: At the time of patient registry in
Distribution of metastatic LNs

Time frame: At the time of 4 years after surgery

Secondary outcomes

Prognostic outcomes according to the length of bowel resection

Time frame: 4 years
Prognostic outcomes according to the central radicality

Time frame: 4 years

Sponsors and collaborators

Lead sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Other

Collaborators

Tokyo Medical and Dental University, Japan

Registry information

Acronym: T-REX

Important dates

Study start: 2013
Primary completion: 2023
Study completion: 2025
First posted: Oct 19, 2016
Registry last updated: Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed